Skip to Content

Posts tagged with "Drug Development"

  • Drug Development

    How Long, Oh Lord, How Long?

    Here we have the prototypical slow summer day. So I’m going to use this one to throw a question out to the readership: those of you in preclinical drug discovery, what’s the longest you’ve personally worked on a project that eventually managed to deliver a clinical candidate? On the not-so-inspiring side, what’s the longest… Read More
  • Drug Development

    A Long Journey to the Capsid

    There’s a fine article at C&E News on Gilead’s capsid inhibitor for HIV. For those not into virology, the capsid is the protein coat that viruses have – it’s their armor, more or less, and disrupting its formation should be a large problem for them. But finding compounds that accomplish that is a large problem… Read More
  • Drug Assays

    Phenotypic Screening: The State of the Art

    I can recommend this article on phenotypic drug discovery from the latest Nature Reviews Drug Discovery. (For the nonspecialists in the crowd, there are two broad categories of screening for drug leads. One is “target-directed”, where you have an idea from other studies about what protein or pathway you want to affect, and you set… Read More
  • Biological News

    Hemophilia: A Proving Ground For Genetic Disease

    There’s very good news for Alnylam (and their partner Sanofi) this morning. They’ve been working on an RNAi approach to hemophilia (fitusiran), targeting expression of antithrombin, a protein which as the name implies which keeps blood from clotting by several different mechanisms. The clinical data that have just come out look very en… Read More
  • Business and Markets

    Following Up

    Here’s a question that I’m not sure if there’s a general answer to: if you’re putting together a drug discovery portfolio, what percentage of the projects should be new ones, and how many should be some form of follow-up? I say that there may not be a general answer because every place I’ve worked has… Read More
  • Biological News

    Thinking About Genetics and Disease

    Robert Plenge has an excellent post here, drawing on this recent paper from authors at Stanford. It’s on the idea of polygenic traits and disease, a very worthwhile subject considering what’s going on in the drug industry these days. I say that because I’ve been making the joke, for some time now, that if you were… Read More
  • Cardiovascular Disease

    Thoughts on An Antibody Failure

    Talking with some drug discovery folks the other day, I said “You know, if you don’t hold your breath when your compound goes into tox testing, you haven’t been doing this stuff long enough”. Well, it’s pretty hard to hold your breath across a full tox study, but you know what I mean. There are… Read More
  • Drug Development

    Cutting (And Re-Cutting) the Research Pie

    Here’s something that goes on inside almost every biopharma research organization, but always happens behind the scenes if you’re not right there at the meetings: resource allocation for projects. That “almost” is in there because the smallest companies don’t have this problem in the same way, since they tend to have o… Read More
  • Drug Assays

    Software Eats the World, But Biology Eats It

    I can strongly recommend this Bruce Booth post at LifeSciVC on computational models in drug discovery. He’s referencing Marc Andreessen’s famous “Why Software Is Eating the World” essay when he titles his “Four Decades of Hacking Biotech and Yet Biology Still Consumes Everything”. To tell you about where Bruce i… Read More
  • Cardiovascular Disease

    The Genomics Revolution Shows Up Late, But Shows Up

    Robert Plenge has an excellent overview of the PCSK9 story up on his site; I recommend it. His take may sound different from mine at first, but I think we’re actually in agreement on a lot of important points. I said that “PCSK9 is about as compelling a story as we’re likely to see in… Read More
...345...